Artelo Biosciences is a biopharmaceutical company dedicated to applying true biopharma discipline in leveraging past research and leading-edge, world-class science to accelerate the development and commercialization of a diverse portfolio of novel, endocannabinoid system modulating therapeutics. Our programs have the potential to dramatically improve patient care in major markets. With our headquarters team in San Diego, California, USA and our European offices in Dublin, Ireland, and Alderley Park, Cheshire, UK, Artelo established a presence in key global biopharma innovation hubs with close access to world-class research expertise. Artelo’s research and development leverages the skill, knowledge and experience of our collaboration partners in Europe and North America.
An undeniable global interest in the study of cannabis treatments inspired the creation of the International Cannabis and Cannabinoids Institute (ICCI), the first Center of Excellence in this field located in the heart of Europe – Czech Republic. ICCI identifies, coordinates and supports global research priorities for the advancement of cannabis and cannabinoid treatments through a multidisciplinary, evidence-based approach that incorporates innovative tools and methods.
ICCIs PFC – Patient Focused Program was created to address issues of quality control and product safety in the cannabis industry and to ensure patients (consumers) and their healthcare providers that they can rely on high-quality medical cannabis products and services. One of its key services is its Education and Training Program.
CBDepot is a pioneer in the production of high-quality natural cannabinoid ingredients. Supplier of bulk and private label of natural cannabinoids.
The company, with roots dating to 2014, has been a leader in helping to establish legal and quality standards for cannabinoid ingredients and the formulation of cannabidiol derivatives that have a fast-growing presence in sectors including food, cosmetics, pharmaceuticals and other health products.
MGC Pharma creates premium phytocannabinoid-based pharmaceutical products from our GMP certified facility in Europe that can be used to treat patients suffering from a variety of symptomatic conditions.
Using a unique labeling system across the range, MGC Pharma has made it simple to understand exactly what Genetic Materials are being utilized in each product. Within the range, each pharmaceutical solution offers a unique combination of cannabinoids in order to address different medical needs. You can learn about the benefits of each of the products below.
We are an European company founded in 2017 and together with our partners we are focused on producing the highest quality Cannabis products. Our products are ecologically produced in according to the legislation of the European Union. All of our products start their life at our G.M.P. facility in Athens, Greece.
GWEE was founded by a group of Cannabis activists and a team of great people who believe that we can all find ourselves mentally and physically healthier with the great power of this plant. Cannabis compounds like CBD have the potential to impacts the lives of millions and by continuing to tell and educate you about the valuable therapeutic properties of this plant, we believe it can improve the quality of life for many and make a big change on this planet. Our goal is to provide an excellent and fast buying process and keep our customers 100% satisfied.
We use supercritical CO2 production. The supercritical (or subcritical) CO2 method uses carbon dioxide under high pressure and extremely low temperatures to isolate, preserve, and maintain the purity and properties of the medicinal oil. Multilevel filtering is used to further process the raw mass and reduce the admixture of fat, lipids and unwanted plant parts. The result is a safe and powerful end product, which is further used in the manufacture of our other products.